2026-04-11T09:44:31Z
https://pub.unibl.org/oai
oai:pub.unibl.org:40236
2024-06-12T14:22:23Z
Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results
/unibl/author/JS Smolen
/unibl/author/JI Choe
/unibl/author/Nenad Prodanović
/unibl/author/J Niebrizidovski
/unibl/author/I Staikov
/unibl/author/E Dokoupilova
/unibl/author/A Baranauskaite
/unibl/author/R Iatsishin
/unibl/author/M Mekić
/unibl/author/V Poravska
/unibl/author/H Ciferska
/unibl/author/K Jedrichovicz-Rosiak
/unibl/author/A Zelinska
/unibl/author/I Lee
/unibl/author/IH Rho
2017
Academic Article
text
10
10
/unibl/sci/idNaucniRad:25129
RHEUMATOLOGY
1462-0324
RHEUMATOLOGY
1462-0324
J. Smolen, J. Choe, N. Prodanović, J. Niebrizidovski, I. Staikov, E. Dokoupilova, A. Baranauskaite, R. Iatsishin, M. Mekić, V. Poravska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, I. Lee, I. Rho, Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results, RHEUMATOLOGY, pp. 10 - 10, 2017